Renee Greer
About Renee Greer
Renee Greer is a Senior Scientist specializing in Immunology, currently working at Asher Biotherapeutics. She focuses on developing in vivo models for therapeutic target identification and validation, with a particular interest in tumor immunology and cancer immunotherapy.
Current Role at Asher Biotherapeutics
Renee Greer serves as a Senior Scientist in Immunology at Asher Biotherapeutics, a position she has held since 2020. In this role, she focuses on the development and application of in vivo models aimed at therapeutic target identification and validation. Her current research centers on assessing the efficacy of cancer immunotherapy approaches, particularly in relation to the tumor microenvironment and tumor immunology.
Previous Experience in Immunology
Before joining Asher Biotherapeutics, Renee Greer worked at Maze Therapeutics as a Senior Scientist in Immunology for one year, from 2019 to 2020. Prior to that, she spent two years at Gritstone Oncology in the same role, from 2017 to 2019. Additionally, she served as a Postdoctoral Research Associate at Oregon State University from 2012 to 2017, where she further developed her expertise in immunology and cancer biology.
Educational Background in Biomedical Science
Renee Greer earned her Doctor of Philosophy (Ph.D.) in Biomedical Science with a focus on Cancer Biology from the University of California, San Francisco, where she studied from 2006 to 2012. Earlier, she completed her Bachelor of Science (B.S.) in Cell/Cellular and Molecular Biology at the University of Michigan from 2002 to 2006. This educational foundation has equipped her with a strong understanding of the biological mechanisms underlying cancer and immunology.
Research Contributions and Publications
Renee Greer has made significant contributions to cancer research, including preclinical data demonstrating the potent antitumor activity of AB821. She is the lead author on a presentation regarding AB821 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. Additionally, she has been involved in research focused on CD8+ T cell selective IL-21 with enhanced bioavailability, showcasing her commitment to advancing cancer immunotherapy.